Abstract：Objective To investigate the clinical effect of Apatinib combined with Compound Kushen Injection in the treatment of malignant tumors.Methods A total of 40 patients with malignant tumors treated in our hospital from March to November in 2017 were selected as subjects.By the random number table method,all patients were evenly divided into two groups,20 cases in each group.In the control group,Apatinib alone was used,while in the research group,Apatinib combined with Compound Kushen Injection were adopted.The clinical effect,adverse reactions and hospitalization expenses and length of stay were observed and compared between the two groups.ResultsThe total effectiveness rate was 90.00%in the research group,which was higher than that in the control group(55.00%),the difference was statistically significant(P＜0.05).The incidence of adverse reactions was 10.00%in the research group,which was lower than that in the control group(40.00%),the difference was statistically significant(P＜0.05).The hospital stay in the research group was(104.19±22.17)d,which was shorter than that of the control group([155.37±32.73]d),the hospitalization expenses in the research group was(20 439.35±10 123.13)yuan,which was less than that of the control group([30 489.17±10 533.71]yuan),the differences were statistically significant(P＜0.05).Conclusion In the treatment of malignant tumors,combination of Apatinib and Compound Kushen Injection can decrease hospitalization expenses,shorten hospital stay,reduce adverse reactions,and achieve a good clinical effect in practicality.
京公网安备 11010502046607号